News from oncopeptides ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

14:54 BST Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which...


31 Jul, 2020, 14:43 BST Number of shares and votes in Oncopeptides

Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being...


30 Jun, 2020, 16:58 BST Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO

Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief...


30 Jun, 2020, 13:17 BST Number of Shares and Votes in Oncopeptides

Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of...


30 Jun, 2020, 07:36 BST Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Drug...


29 Jun, 2020, 16:53 BST Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera's drug development facility in ...


15 Jun, 2020, 07:15 BST Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the full top-line results from the pivotal phase 2 HORIZON study, evaluating...


11 Jun, 2020, 08:47 BST Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13th, focusing on...


01 Jun, 2020, 07:25 BST New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a...


29 May, 2020, 10:24 BST Number of shares and votes in Oncopeptides

ncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being...


28 May, 2020, 07:15 BST Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the company starts patient enrollment to its clinical program following the temporary...


26 May, 2020, 16:46 BST Bulletin From the Annual General Meeting in Oncopeptides AB (publ)

Oncopeptides AB (publ)'s (ONCO) Annual General Meeting 2020 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the...


26 May, 2020, 07:32 BST Oncopeptides AB: Interim Report Q1 2020

Financial overview January 1 - March 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 297.3 M (loss: 134.1) Loss per share, ...


22 May, 2020, 07:21 BST Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of...


15 May, 2020, 11:28 BST Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen...


14 May, 2020, 14:15 BST Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical...


13 May, 2020, 16:20 BST Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society...


28 Apr, 2020, 13:51 BST Oncopeptides Annual Report 2019

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the annual report for 2019 is now available on the company's website. The report...


22 Apr, 2020, 08:04 BST Annual General Meeting in Oncopeptides AB (publ)

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, ("Oncopeptides" or the...


02 Apr, 2020, 07:30 BST Oncopeptides Strengthens its Corporate Communications Function by Appointing Rolf Gulliksen as Global Head of Corporate Communications

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate communications. Rolf has 30...


26 Mar, 2020, 09:22 GMT Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melflufen in...


24 Mar, 2020, 02:48 GMT The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1)

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in...


20 Mar, 2020, 07:15 GMT Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronavirus...


02 Mar, 2020, 07:19 GMT Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides. Karolina has 15...


24 Jan, 2020, 17:40 GMT Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET)

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that it will host a webcast at 11am (CET) on Monday, January 27th 2020 where CEO Jakob...